Regulatory AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer BioSpaceDecnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer.HematologyRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioSpace Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer. Hematology Read full story Post navigation Previous: November date set for FDA decision on Sanofi’s Gaucher drugNext: GSK hails ‘unprecedented’ cure rates with hep B drug Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026